English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/214774
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Characterization of a Human Anti-Tumoral NK Cell Population Expanded After BCG Treatment of Leukocytes

AuthorsGarcía-Cuesta, Eva María; Esteso, Gloria; Ashiru, Omedela; López-Cobo, Sheila; Álvarez-Maestro, Mario; Linares, Ana; Ho, Mei M.; Martinez-Piñeiro, Luis; Reyburn, H. T. ; Valés-Gómez, Mar
KeywordsBCG
CD56bright
NK cell differentiation
NK receptor
chemokines
cytokines
Issue DateFeb-2017
PublisherTaylor & Francis
CitationOncoimmunology 6(4): e1293212 (2017)
AbstractImmunotherapy, via intra-vesical instillations of BCG, is the therapy of choice for patients with high-risk non-muscle invasive bladder cancer. The subsequent recruitment of lymphocytes and myeloid cells, as well as the release of cytokines and chemokines, is believed to induce a local immune response that eliminates these tumors, but the detailed mechanisms of action of this therapy are not well understood. Here, we have studied the phenotype and function of the responding lymphocyte populations as well as the spectrum of cytokines and chemokines produced in an in vitro model of human peripheral blood mononuclear cells (PBMCs) co-cultured with BCG. Natural killer (NK) cell activation was a prominent feature of this immune response and we have studied the expansion of this lymphocyte population in detail. We show that, after BCG stimulation, CD56dim NK cells proliferate, upregulate CD56, but maintain the expression of CD16 and the ability to mediate ADCC. CD56bright NK cells also contribute to this expansion by increasing CD16 and KIR expression. These unconventional CD56bright cells efficiently degranulated against bladder cancer cells and the expansion of this population required the release of soluble factors by other immune cells in the context of BCG. Consistent with these in vitro data, a small, but significant increase in the intensity of CD16 expression was noted in peripheral blood CD56bright cells from bladder cancer patients undergoing BCG therapy, that was not observed in patients treated with mitomycin-C instillations. These observations suggest that activation of NK cells may be an important component of the anti-tumoral immune response triggered by BCG therapy in bladder cancer.
Publisher version (URL)https://doi.org/10.1080/2162402X.2017.1293212
URIhttp://hdl.handle.net/10261/214774
DOI10.1080/2162402X.2017.1293212
ISSN2162-4011
E-ISSN2162-402X
Appears in Collections:(CNB) Artículos
Files in This Item:
File Description SizeFormat 
Valés-Gómez, M. - Oncoimmunology . 6- 2017.pdfArtículo pincipal5,14 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.